Rhabdomyosarcoma treatment cost in India typically involves a PET-CT scan running Price on request to Price on request for accurate staging. Primary interventions like removal of rhabdomyosarcoma cost AUD $6,330 to AUD $13,364, while complex integrated protocols run AUD $35,169 to AUD $91,440. Total expenses depend on the patient's age and the specific oncology techniques used. Australians often save 70–80% compared to local private healthcare costs. Prime locations for this treatment include Bengaluru, Gurgaon, and Chennai.
Typical Rhabdomyosarcoma Treatment Costs in India
Bookimed Expert Insight: For paediatric cases, hospitals with dedicated units provide the safest care. Artemis Hospitals features specialists like Dr Gaurav Kharya, who focuses on complex paediatric blood disorders and cancers. Patients requiring advanced technology find value at Fortis Gurgaon, ranked among the most technically advanced hospitals globally. Large centres like Global Hospital Chennai offer multidisciplinary teams, which is vital for cases needing integrated surgical and transplant expertise.
| India | Thailand | Turkey | |
| Removal of rhabdomyosarcoma | from AUD $6,330 | from AUD $39,390 | from AUD $21,102 |
| Radiation therapy for colorectal cancer | from AUD $4,502 | from AUD $7,737 | from AUD $9,847 |
| Radiation Therapy for Sarcomas | from AUD $6,330 | from AUD $9,847 | from AUD $4,572 |
| Chemotherapy for breast cancer | from AUD $4,924 | from AUD $4,220 | from AUD $1,688 |
| Complex treatment of rhabdomyosarcoma | from AUD $35,169 | - | from AUD $63,305 |
No hidden fees – just official clinic prices. Pay at the clinic for Rhabdomyosarcoma treatment and use a flexible instalment plan if needed.
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Rhabdomyosarcoma treatment and have the necessary licenses to serve international patients worldwide.
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Rhabdomyosarcoma treatment journey.
Dr Gaurav Kharya is a specialist paediatric hematologist-oncologist who leads bone marrow transplant services at Artemis Hospitals.
Leading Indian hospitals for rhabdomyosarcoma treatment include Global Hospital Chennai. Fortis Gurgaon and HCG Manavata Cancer Centre are also included. These NABH-accredited facilities provide multidisciplinary care using TomoTherapy, PET-CT, and TrueBeam technology. Specialist oncology teams follow international protocols to manage surgery and intensive chemotherapy cycles.
Bookimed Expert Insight: Indian oncology hubs are shifting toward super-specialisation in paediatric sarcomas. Major centres like Manipal Hospitals serve 2,000,000 patients annually. However, HCG Manavata stands out by auditing its research institute through the US-FDA. This suggests these centres maintain global data standards for rare soft-tissue tumours like rhabdomyosarcoma.
Patient Consensus: Patients highlight that Indian specialists are first-rate for soft-tissue sarcomas. Many suggest having Australian pathology reviewed first. This can confirm embryonal or alveolar subtypes before starting chemotherapy.
Rhabdomyosarcoma success rates in India vary by risk group, with five-year survival between 40% and 77% overall. Low-risk tumours show 90% survival in leading Indian oncology centres. Intermediate-risk cases often see 70% survival through intensive chemotherapy, surgery, and specialised radiation therapy.
Bookimed Expert Insight: While India lacks sarcoma-specific CAR-T therapy, oncology units here specialise in massive surgical volumes. HCG Manavata Cancer Centre treats over 75,000 patients every year. This high volume allows specialists to refine complex surgical removals that smaller clinics cannot perform.
Patient Consensus: Patients in India note that tumour shrinkage during radiation takes time to show on scans. Management of intense nausea and fatigue is essential during the initial week of chemotherapy.
India provides advanced radiotherapy like proton therapy for rhabdomyosarcoma. The Apollo Proton Cancer Centre in Chennai specialises in this treatment. It uses pencil beam scanning to target tumours precisely. This technology protects healthy tissue in paediatric cases and reduces side effects.
Bookimed Expert Insight: Indian radiotherapy centres have a unique infrastructure advantage for paediatric cases. HCG Manavata Cancer Centre in Nashik treated over 75,000 patients. It also holds US-FDA audit approval for clinical research. This level of volume allows specialists to refine protocols for rare sarcomas. Smaller regional centres rarely see these sarcomas.
Patient Consensus: Families note that proton therapy effectively manages side effects during child oncology treatments in India. They also mention that standard radiotherapy combined with chemotherapy remains a reliable and manageable path. This is for alveolar rhabdomyosarcoma cases.
Rhabdomyosarcoma treatment in India uses a multimodal approach combining chemotherapy, surgical resection, and radiation therapy. Specialists like Dr Gaurav Kharya at Artemis Hospitals focus on paediatric cases. Indian centres provide rapid access to advanced PET-CT diagnostics. They also offer TrueBeam STx radiation to manage systemic spread.
Bookimed Expert Insight: Indian oncology centres often provide faster access to treatment than many Western systems. HCG Manavata Cancer Centre has performed over 65,000 surgeries and treated 25,000 radiation cases. This massive volume means Indian specialists manage rare rhabdomyosarcoma presentations more frequently. They manage them more often than specialists in smaller regional hubs.
Patient Consensus: Patients find that treatment in India often starts within days of diagnosis. They highlight that the year-long chemotherapy protocol alongside radiation is manageable with proper supportive care.
India provides specialised paediatric oncologists and multidisciplinary sarcoma teams at major cancer centres. These specialists manage childhood rhabdomyosarcoma using integrated chemotherapy, surgery, and radiation. They work within JCI or NABH-accredited hospitals. Facilities like HCG Manavata and Manipal Hospitals maintain dedicated paediatric oncology departments for these complex cases.
Bookimed Expert Insight: Many patients seek doctors in major hubs like Delhi or Mumbai. However, regional centres offer comparable technology. HCG Manavata in Nashik treats 75,000+ patients annually. It was the first in its region with TomoTherapy-H. This technology allows precise radiation that spares a child's developing healthy tissue during sarcoma treatment.
Patient Consensus: Families find it essential to choose hospitals with dedicated paediatric oncology departments. They prefer these over general ones. Patients recommend sharing full pathology reports with Indian specialists early. This helps confirm experience with specific rhabdomyosarcoma subtypes.
Clinical trials for Rhabdomyosarcoma are available in India. Leading centres such as HCG Manavata Cancer Centre and Tata Memorial Hospital actively run research. These trials often focus on paediatric oncology and soft tissue sarcomas. Many studies involve international collaborations, giving access to novel treatment protocols.
Bookimed Expert Insight: India excels in fast treatment initiation, with virtually no waiting times for chemotherapy. Some immunotherapy trials are limited to the US. Still, Indian centres like HCG Manavata serve 75,000+ patients each year. This high volume supports robust data collection in Phase 3 trials comparing new protocols against standard care.
Patient Consensus: Patients find that starting standard chemotherapy in India is incredibly fast. Most families focus on immediate surgery and chemo. They also check for novel agents like pan-KRAS inhibitors through local oncologists.